43. Iliev R, Kleinova R, Juracek J et al (2016) Overexpression of long non-coding RNA TUG1
predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade
muscle-invasive bladder cancer. Tumor Biol 37:13385–13390. https://doi.org/10.1007/
s13277-016-5177-9
44. Cao J, Han X, Qi X et al (2017) TUG1 promotes osteosarcoma tumorigenesis by upregulating
EZH2 expression via MIR-144-3p. Int J Oncol 51:1115–1123. https://doi.org/10.3892/ijo.
2017.4110
45. Huang M, Chen W, Qi F et al (2015) Long non-coding RNA TUG1 is up-regulated in
hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetic silencing
of KLF2. Mol Cancer 14:165. https://doi.org/10.1186/s12943-015-0431-0
46. Zhou Y, Lu Y, Li R et al (2017) Prognostic role of long non-coding RNA TUG1 expression
in various cancers: a meta-analysis. Oncotarget 8:100499–100507. https://doi.org/10.18632/
oncotarget.20037
47. Sattari A, Siddiqui H, Moshiri F et al (2016) Upregulation of long noncoding RNA MIAT
in aggressive form of chronic lymphocytic leukemias. Oncotarget 7:54174–54182. https://doi.
org/10.18632/oncotarget.11099
48. Lai I-L, Yang C-A, Lin P-C et al (2017) Long noncoding RNA MIAT promotes non-small
cell lung cancer proliferation and metastasis through MMP9 activation. Oncotarget
8:98148–98162. https://doi.org/10.18632/oncotarget.21465
49. Huarte M, Guttman M, Feldser D et al (2010) A large intergenic noncoding RNA induced
by p53 mediates global gene repression in the p53 response. Cell 142:409–419. https://doi.org/
10.1016/j.cell.2010.06.040
50. Diaz-Lagares A, Crujeiras AB, Lopez-Serra P et al (2016) Epigenetic inactivation of the
p53-induced long noncoding RNA TP53 target 1 in human cancer. Proc Natl Acad Sci
113:E7535–E7544. https://doi.org/10.1073/pnas.1608585113
51. Jürchott K, Kuban RJ, Krech T et al (2010) Identification of Y-box binding protein 1 as a core
regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS
Genet 6:1–19. https://doi.org/10.1371/journal.pgen.1001231
52. Özeş AR, Miller DF, Özeş ON et al (2016) NF-κB-HOTAIR axis links DNA damage
response, chemoresistance and cellular senescence in ovarian cancer Ali. Oncogene
35:5350–5361. https://doi.org/10.1038/onc.2016.75
53. Özeş AR, Wang Y, Zong X et al (2017) Therapeutic targeting using tumor specific peptides
inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep 7:1–11.
https://doi.org/10.1038/s41598-017-00966-3
54. Lee ST, Li Z, Wu Z et al (2011) Context-specific regulation of NF-κB target gene
expression by EZH2 in breast cancers. Mol Cell 43:798–810. https://doi.org/10.1016/j.
molcel.2011.08.011
55. Chu C, Spitale RC, Chang HY (2015) Technologies to probe functions and mechanisms
of long noncoding RNAs. Nat Struct Mol Biol 22:29–35. https://doi.org/10.1038/nsmb.2921
56. Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche.
Cell 143:355–366. https://doi.org/10.1016/j.cell.2010.09.043
57. Egholm M, Buchardt O, Christensen L et al (1993) PNA hybridizes to complementary
oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365:566–568.
https://doi.org/10.1038/365566a0
58. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms
of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol
50:259–293. https://doi.org/10.1146/annurev.pharmtox.010909.105654
59. Landen CN, Goodman B, Katre AA et al (2010) Targeting aldehyde dehydrogenase
cancer stem cells in ovarian cancer. Mol Cancer Ther 9:3186–3199. https://doi.org/10.1158/
1535-7163.MCT-10-0563
60. Thévenin D, An M, Engelman DM (2009) pHLIP-mediated translocation of membraneimpermeable molecules into cells. Chem Biol 16:754–762. https://doi.org/10.1016/j.
chembiol.2009.06.006
Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers. . .
423
predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade
muscle-invasive bladder cancer. Tumor Biol 37:13385–13390. https://doi.org/10.1007/
s13277-016-5177-9
44. Cao J, Han X, Qi X et al (2017) TUG1 promotes osteosarcoma tumorigenesis by upregulating
EZH2 expression via MIR-144-3p. Int J Oncol 51:1115–1123. https://doi.org/10.3892/ijo.
2017.4110
45. Huang M, Chen W, Qi F et al (2015) Long non-coding RNA TUG1 is up-regulated in
hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetic silencing
of KLF2. Mol Cancer 14:165. https://doi.org/10.1186/s12943-015-0431-0
46. Zhou Y, Lu Y, Li R et al (2017) Prognostic role of long non-coding RNA TUG1 expression
in various cancers: a meta-analysis. Oncotarget 8:100499–100507. https://doi.org/10.18632/
oncotarget.20037
47. Sattari A, Siddiqui H, Moshiri F et al (2016) Upregulation of long noncoding RNA MIAT
in aggressive form of chronic lymphocytic leukemias. Oncotarget 7:54174–54182. https://doi.
org/10.18632/oncotarget.11099
48. Lai I-L, Yang C-A, Lin P-C et al (2017) Long noncoding RNA MIAT promotes non-small
cell lung cancer proliferation and metastasis through MMP9 activation. Oncotarget
8:98148–98162. https://doi.org/10.18632/oncotarget.21465
49. Huarte M, Guttman M, Feldser D et al (2010) A large intergenic noncoding RNA induced
by p53 mediates global gene repression in the p53 response. Cell 142:409–419. https://doi.org/
10.1016/j.cell.2010.06.040
50. Diaz-Lagares A, Crujeiras AB, Lopez-Serra P et al (2016) Epigenetic inactivation of the
p53-induced long noncoding RNA TP53 target 1 in human cancer. Proc Natl Acad Sci
113:E7535–E7544. https://doi.org/10.1073/pnas.1608585113
51. Jürchott K, Kuban RJ, Krech T et al (2010) Identification of Y-box binding protein 1 as a core
regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS
Genet 6:1–19. https://doi.org/10.1371/journal.pgen.1001231
52. Özeş AR, Miller DF, Özeş ON et al (2016) NF-κB-HOTAIR axis links DNA damage
response, chemoresistance and cellular senescence in ovarian cancer Ali. Oncogene
35:5350–5361. https://doi.org/10.1038/onc.2016.75
53. Özeş AR, Wang Y, Zong X et al (2017) Therapeutic targeting using tumor specific peptides
inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep 7:1–11.
https://doi.org/10.1038/s41598-017-00966-3
54. Lee ST, Li Z, Wu Z et al (2011) Context-specific regulation of NF-κB target gene
expression by EZH2 in breast cancers. Mol Cell 43:798–810. https://doi.org/10.1016/j.
molcel.2011.08.011
55. Chu C, Spitale RC, Chang HY (2015) Technologies to probe functions and mechanisms
of long noncoding RNAs. Nat Struct Mol Biol 22:29–35. https://doi.org/10.1038/nsmb.2921
56. Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche.
Cell 143:355–366. https://doi.org/10.1016/j.cell.2010.09.043
57. Egholm M, Buchardt O, Christensen L et al (1993) PNA hybridizes to complementary
oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365:566–568.
https://doi.org/10.1038/365566a0
58. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms
of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol
50:259–293. https://doi.org/10.1146/annurev.pharmtox.010909.105654
59. Landen CN, Goodman B, Katre AA et al (2010) Targeting aldehyde dehydrogenase
cancer stem cells in ovarian cancer. Mol Cancer Ther 9:3186–3199. https://doi.org/10.1158/
1535-7163.MCT-10-0563
60. Thévenin D, An M, Engelman DM (2009) pHLIP-mediated translocation of membraneimpermeable molecules into cells. Chem Biol 16:754–762. https://doi.org/10.1016/j.
chembiol.2009.06.006
Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers. . .
423